Eligible patients had confirmed HCC with disease unresectable or amenable to other localised therapies, Child-Pugh A liver status, and no prior systemic therapy involving the VEGF or m-TOR class of agents. This evidence concerns the gene VEGFA and hepatocellular carcinoma.